Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.5050 (5.47%) ($10.5050 - $10.5050) on Fri. Jan. 14, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4% (three month average) | RSI | 39 | Latest Price | $10.5050(5.47%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.8% a day on average for past five trading days. | Weekly Trend | FOLD declines -8.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(61%) IWO(53%) IWM(50%) IWC(49%) XBI(48%) | Factors Impacting FOLD price | FOLD will decline at least -2% in a week (0% probabilities). VIXM(-29%) VXX(-13%) UUP(-12%) UNG(-9%) EDOC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2% (StdDev 4%) | Hourly BBV | 2.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-4.61(-143.88%) | Resistance Level | $11.29 | 5 Day Moving Average | $9.9(6.11%) | 10 Day Moving Average | $10.92(-3.8%) | 20 Day Moving Average | $11.29(-6.95%) | To recent high | -15.7% | To recent low | 11.3% | Market Cap | $2.713b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |